Sydbank: Uncertain what FDA decision means for Novo
It is still too soon to gauge the consequences of the US FDA’s demand for additional info from Novo Nordisk regarding a new product, according to an analyst.
BY MORTEN STEEN
Novo Nordisk will have to wait patiently to see its new rapid-acting insulin aspart enter the US market after the FDA sent a complete response letter to the Danish drug group over the weekend.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo suffers regulatory setback in the US
For abonnenter
